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Background: After alleged stop of transmission of schistosomiasis and further down the line in post elimination
settings, sensitive tools are required to monitor infection status to prevent potential re-emergence. In Rahala, where
transmission cycle of Schistosoma haematobium is interrupted since 2004 but where 30% of snails are still infected
by S. bovis, potential human S. bovis infection can’t be excluded. As methods based on egg-counts do not provide
the required sensitivity, antibody or antigen assays are envisaged as the most appropriate tools for this type of
monitoring.
Methods: In this pilot study, the performances of three assays were compared: two commercially available
antibody tests (ELISA and haemagglutination format) indicating exposure, and an antigen test (lateral flow strip
format) demonstrating active infection. All 37 recruited study participants resided in Rahala (Akka, province Tata,
Morocco). Participants had been diagnosed and cured from schistosomiasis in the period between 1983 and 2003.
In 2015 these asymptomatic participants provided fresh clinical samples (blood and urine) for analysis with the
aforementioned diagnostics tests.
Results: No eggs were identified in the urine of the 37 participants. The haemagglutination test indicated 6
antibody positives whereas the ELISA indicated 28 antibody positives, one indecisive and one false positive. ELISA
and haemagglutination results matched for 18 individuals, amongst which 5 out of 6 haemagglutination positives.
With the antigen test (performed on paired serum and urine samples), serum from two participants (cured 21 and
32 years ago) indicated the presence of low levels of the highly specific Schistosoma circulating anodic antigen
(CAA), demonstrating low worm level infections (less than 5 pg/ml corresponding to probably single worm pair).
One tested also CAA positive with urine. ELISA indicated the presence of human anti-Schistosoma antibodies in
these two CAA positive cases, haemagglutination results were negative.
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Conclusions: To prevent reemergence of schistosomiasis in Morocco current monitoring programs require specific
protocols that include testing of antibody positives for active infection by the UCP-LF CAA test, the appropriate
diagnostic tool to identify Schistosoma low grade infections in travelers, immigrants and assumed cured cases.
The test is genus specific will also identify infections related to S. bovis.
Keywords: Schistosomiasis, Transmission stop, Elimination, Monitoring, Antibody test, Antigen test, Circulating
Anodic Antigen (CAA), Active infectionMultilingual abstracts
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Background
Schistosoma haematobium is responsible for a heavy
burden of disease affecting more than 100 million people
in sub-Saharan Africa [1, 2]. Effective transmission con-
trol of the infection includes accurate (high sensitivity)
diagnosis, (preventive) chemotherapy, snail control, sani-
tation, safe water supplies, and human behavioral change
strategies [3]. Morocco, after nearly three decades of ef-
fort, was successful in the elimination of urogenital
schistosomiasis caused by S. haematobium. Since 2004
no new local cases were reported [4]. In 2009 validation
of interruption of transmission was commenced with the
initiation of a national serological survey (using enzyme-
linked immunoelectrotransfer blot, EITB) screening for
human antibodies against S. haematobium in children,
followed by a national molecular malacology survey ana-
lyzing the prevalence of infected snails (the intermediate
host). The results confirmed interruption of transmis-
sion and indicated progress towards elimination as it
showed that none of children or the collected snails was
infected by S. haematobium [5, 6]. However, given that
the exact parasite life spans and the distribution of the
post-treatment antibody responses across the whole
population are not fully understood [1, 7], prevention of
reemerging required a vigilant survey strategy. It seems
prudent to carefully monitor travelers and immigrants
from endemic countries and other potentially high risk
groups.
Various protocols for the diagnosis and surveillance of
urogenital schistosomiasis have been proposed but none
with optimal performance characteristics for sensitive
and specific point-of-care (POC) applications [8]. Rapid
Schistosoma anti-egg antibody strip assays for POC
applications have been described [9] and may even be
used with non-invasive bodily fluids as urine and saliva.
Moreover, diagnosis by detecting specific antibodies
seems to be more sensitive than the traditional method
detection of eggs in urine [10]. In post-transmission and
elimination area, antibody detection demonstrating
exposure (not active infections) to the pathogen mightbe suitable for the group born after transmission stop.
For older and previously infected individuals [11–13],
antibody detection methods will not be useful as one
needs to distinguish past cured infections from current
ongoing active infections.
In order to incorporate antibody diagnosis in routine
clinical laboratory practice, a robust easy to use, medium
to high throughput, sensitive and specific test is needed.
Unfortunately, the previously successfully evaluated
enzyme-linked immunoelectrotransfer blot (EITB) is not
readily available for large scale testing because of the
high cost of the specific microsomal antigens used for
antibody-capture. Only a few other serological antibody
tests for schistosomiasis are commercially available but
none of them have been evaluated for use in post elimin-
ation settings. More recent molecular diagnostics that
target schistosome egg DNA isolated from urine offering
high sensitivity and specificity are available, but these
methods are still costly, do rely on the presence of eggs,
and require significant laboratory infrastructure including
qualified staff [8]. A better alternative is the diagnostic test
to determine active infections with any Schistosoma
species (including the veterinarian species) by detection of
a schistosome-derived (regurgitated) genus-specific carbo-
hydrate antigen. This lateral flow (LF) based test applies a
novel ultrasensitive fluorescent label (upconverting phos-
phor, UCP) for detection of the Schistosoma circulating
anodic antigen (CAA) in human circulation and can be
used with various body fluids. It allows convenient storage
and worldwide shipping at ambient temperature in its
current user-friendly dry reagent format [14]. Enhanced
sensitivity of this UCP-LF CAA strip testis achieved utiliz-
ing centrifugal filtration devices which permit larger sam-
ple input. The analysis of a sample volume of 0.5 ml
serum or 2 ml urine is believed to allow detection of single
worm infections [15]; these two assays are referred to
respectively as the SCAA500 and UCAA2000 test, with ‘S’
indicting serum, ‘U’ urine and the number the amount of
sample (in μl) concentrated and analyzed on the strip. The
amount of sample input is flexible, but relates directly to
the achieved analytical sensitivity.
In the current study, three assays were assessed for their
potential to accurately evaluate the present status of past
schistosomiasis cases: i) indirect haemagglutination assay
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flow antigen test. Both the IHA and ELISA antibody test
are based on detection of the presence of human antibody
against adult worm antigens, detecting past exposure and
ongoing infections. The UCP-LF CAA tests detects
Schistosoma worm antigen (CAA), and as CAA is rapidly
cleared is specific for active infections; testing was
performed with paired samples, 150 μl serum and 475 μl
urine (SCAA150 and UCAA475) allowing detection of
low grade infections. Primary goal of this study is to evalu-
ate diagnostic tools for an appropriate and affordable
strategy and protocol for accurate monitoring of post-
elimination settings, specifically to prevent reemerging of
urogenital schistosomiasis in Morocco. Individuals en-
rolled in this study allowed assessment of the diagnostic
tests for monitoring past urinary schistosomiasis cases
considered cured before transmission-stop was declared
in 2004.Methods
Study area
The pilot study was conducted in Tata province, located
in south-west Morocco. This province has been one of
the oldest and largest foci of urogenital schistosomiasis
in Morocco. In 1983, a total of 3 371 cases were detected
there, with an incidence rate of 34.4 cases per 1 000 resi-
dents. In Tata, we selected Akka (more specific, Rahala
area) for sampling, in this area the last known cases of
schistosomiasis were detected [16]. In 2003, schistosom-
iasis in Akka accounted for 60% (75 cases) of the total
number of cases reported in Morocco. Interruption of
transmission was claimed in 2004 and since then no new
active autochthonous schistosomiasis cases have been
reported. In 2015, serological and molecular-malacology
survey showed that none of the children and the col-
lected snails were infected by S. haematobium, however
about 30% of snails were infected by S. bovis [6].Patients and samples
In March 2015, a list of 100 past patients for urinary
schistosomiasis treated at Rahala and considered cured,
was compiled and archived clinical data collected. Inclu-
sion criteria was: being listed in the register of cases in-
fected and treated and always living in Tata; for negative
control samples individuals stated that they had never
had water contact in endemic areas.
The applied inclusion criteria were: being listed in the
register of cases infected and treated, and have always
lived in Tata since the drug treatment. Individuals not
living in Tata were excluded. Negative controls stated
that they had never had water contact in endemic areas.
An administrator of parasitic diseases contacted the
100 individuals to inform them regarding the objectivesof the current parasitological survey including a new
high sensitivity diagnostic screening tool.
The administrator first contacted all cases detected in
2003, and then continued with preceding years until
100individuals agreed to participate to the survey.
Unfortunately, at the survey week, only 37 individuals of
the 100 concurred individuals participated. From these
individuals, age, sex and location were recorded and
5 ml whole blood for serum and 50 ml urine was
collected. Urine was used for Schistosoma egg determin-
ation, blood was tested for detection of human antibodies
against Schistosoma as well as detection of Schistosoma
antigen, CAA (circulating anodic antigen). Eggs and CAA
are indicative for active (ongoing) Schistosoma infection,
whereas antibody detection is indicative for exposure but
cannot distinguish between past (cured) and current infec-
tion. Negative control samples were included obtained
from five individuals (sample id T1–T5) from a non-
endemic region (Rabat); individuals stated that they had
never had water contact in endemic areas. A high positive
control included (sample id T6) was obtained from CDC
and was used in the last national serological survey in
2009 [5].
Parasitological examination, egg detection
All individuals were invited to a communal health
center, where the parasitological examination of urine
(detection of eggs) was conducted by a team of trained
laboratory technicians. From each study participant,
50 ml urine was obtained between 10:00 AM and
2:00 PM, after physical exercise, and collected in prop-
erly labeled disposable containers. Containers were cen-
trifuged for 2 mins at 2 000 rpm, and the pellet was
thereafter examined microscopically for the presence of
the characteristic S. haematobium egg using 10× and
40× objectives. Urine samples containing schistosome
egg(s) were recorded as positive; absence of eggs of
schistosomes was considered negative [17]. Samples
(40 ml) were packed carefully and transported to the
laboratory in a cooler at 4 °C for storage at −20 °C.
Aliquots of 450 μl were shipped to the Netherlands on
dry ice for UCP-LF CAA testing at Leiden University
Medical Center (LUMC).
Serological assays, antibody detection by IHA and ELISA
Blood samples were centrifuged for 10 min at 1 500 rpm
to collect serum. From each individual, 2 ml of serum
was aliquoted over two microfuge tubes. Samples were
properly packed, cooled and transferred to the labora-
tory of the National Institute of Hygiene at Rabat for
antibody analysis. The presence of human antibodies
against S. haematobium was in vestigated with two
assays: i) schistosomiasis Fumouze, IHA test from
Fumouze Diagnostics (Levallois-Perret, France); ii) the
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with soluble antigen from male and female worms of the
Puerto Rico Schistosoma strain from NovaTec Immun-
diagnostica (Dietzenbach, Germany). As reported by
Kinke et al., the combination of IHA and ELISA is
informative for diagnosis of imported schistosomiasis in
non-endemic areas [18].
The IHA test kit was used according to the manufac-
turer’s instruction. Briefly: 50 μl of a 1:20 initial dilution
of each serum was subjected to further two-fold serial
dilutions, and 10 μl of sheep red blood cells sensitized
with S. mansoni adult WA was added to each diluted
sample. Positive and negative control sera and non-
sensitized red blood cells were included in each test as
controls for naturally occurring antibodies [10]. All sera
were tested in duplicate. The results were evaluated with
a cutoff of 1:80.
The ELISA antibody test provides a qualitative result
and detects IgG class antibodies against Schistosoma in
humans and requires a sample input of 10 μl serum.
The immune complex formed by the bound conjugate is
visualized by adding Tetramethylbenzidine (TMB) sub-
strate. Absorbance was measured at 450/620 nm within
30 min after addition of the stop solution. Samples were
classified as positive, negative, or indeterminate accord-
ing to the manufacturer’s cutoff values.Schistosoma antigen detection in serum and urine by
UCP-LF CAA
Serum and urine samples were sent to LUMC (the
Netherlands) for examination with the UCP-LF CAA
test. Serum samples included six control samples labeled
T1-6, with T1-5 being negative controls and T6 being a
high positive control. Testing at LUMC was done single
blind, without specific sample information. Serum
samples were tested with the SCAA150 assay and urine
samples were tested with the UCAA475 assay [9].
Briefly, 150 μl of serum (SCAA150) or 475 μl of urine
(UCAA475) was extracted with an equal volume of 4%
(w/v) TCA. Samples were centrifuged and the clear
supernatant (200 and 950 μl for serum and urine, re-
spectively) concentrated to 20 μl using 0.5 mL Amicon
Ultra Centrifugal Filter Devices (10 kDa cutoff Ultra-0.5
columns, Millipore Corp); urine samples required an
extra loading step as the TCA supernatant exceeded the
maximum loading capacity of the 0.5 ml columns.
Concentrated samples (20 μl) were tested in singlet with
the UCP-LF CAA strip assay as described previously [9]
with a lower limit of detection of 2.5 and 0.5 pg/ml
CAA in serum and urine, respectively. Standard series of
CAA spiked in normal human serum or urine were
processed along with the clinical samples allowing accur-
ate determination of CAA concentrations.Results
Study group
Fresh clinical samples from former urinary schistosomiasis
cases (identified, treated and considered cured in the
period 1983 through 2003) were analyzed for the presence
eggs, anti-Schistosoma antibody and Schistosoma antigen.
All participants resided in Akka (Rahala area) and
were considered healthy in 2015. Of the 37 partici-
pants, 65% (n = 24) were male and 35% (n = 13) were
female. The age distribution when sampling for the
current study was: 59% 21–40 years of age, 33% 41–
60 years and 8% over 61 years. In the past, when in-
fection was diagnosed and treated (between 1983 and
2003), the age distribution of this group was 8%
under 7 years, 59% (7–14), 30% (15–49), 3% above 50
(eldest being 75).
Schistosoma egg detection in urine
Parasitology, microscopic examination of the sediment
of the urine samples, indicated that none of individuals
harbored Schistosoma eggs.
Anti-Schistosoma antibody detection in serum
Serology as examined by IHA and ELISA indicated the
presence of antibodies against S. haematobium in 6
(16%) and 28 (76%) subjects, respectively (Table 2). Note
that the number of positives for the IHA test would de-
crease to 1 (ID# 22), when a cutoff threshold of 1:160
was used as suggested by the manufacturer. The 5 extra
IHA positives (ID# 8, 9, 10, 30 and 33) all tested positive
with the ELISA, implying that the lower cutoff threshold
was acceptable. When combining IHA and ELISA test-
ing 29 individuals were antibody positive.
The positive control sample tested positive with both
assays. The 5 egg-negative controls without schistosom-
iasis background from Rabat (a non-endemic region)
were antibody negative except for one sample (ID# T1)
which returned an antibody positive test result with the
ELISA (Table 3).
Schistosoma antigen detection in urine and serum
Serum and urine samples were analyzed for the presence
of CAA using a sample input of 150 (SCAA150) or 475
(UCAA475) μl, serum and urine respectively. Standard
series of CAA spiked in negative human serum and
urine were tested alongside and used to calculate CAA
levels in the clinical samples (Fig. 1).
Serum
Samples from two individuals (ID# 26 and 35) scored
CAA levels in the SCAA150 test above the serum cutoff
threshold of 2.5 pg/ml; 4.2 and 3.5 pg/mL, respectively.
Both samples were also antibody positive with the ELISA
test. For three individuals (ID# 13, 15 and 16) the amount
Fig. 1 CAA standard series in serum and urine analyzed with UCP-LF. Standard series of CAA spiked in urine and serum. Analyzed with the
Schistosoma UCP-LF CAA concentration assay utilizing a sample input of 150 μl serum or 475 μl urine, respectively the SCAA150 and UCAA475
test. CAA concentrations are plotted (double logarithmic graph) against the Ratio value obtained with the UCP-LF CAA test. The Ratio value is the
signal measured at the Test line (T, CAA capture line) divided by the Flow Control (FC) line on the LF strip
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samples scored below cutoff threshold (Tables 1 and 2).
Negative control samples all scored below the cutoff
threshold (Table 3) with an average value of 0.84 and
highest value of 1.7 (ID# T5). The positive control T6
indicated a serum CAA level >100 pg/ml.Urine
Only one urine sample (ID# 26) scored a CAA level in
the UCAA475 test above the urine cutoff threshold;
0.85 pg/ml. This CAA-positive urine sample had a
matching CAA-positive serum sample and an ELISA
antibody positive test result. All other samples scoredTable 1 Participant information and diagnostic test results
Participant information Diagnos
ID Age Gender Diagnosed YADb Microsc
26 32 Male 1994 21 Negativ
35 47 Male 1983 32 Negativ
aDiagnostic tests results from analysis performed in 2015
bYAD: number of years after initial diagnosis and drug treatmentbelow the 0.5 pg/ml cutoff threshold for the UCAA950
urine test.
Discussion
Accurate diagnosis of Schistosoma infections challenging
in low endemic setting and countries as Morocco where
transmission stop is declared and the urogenital schisto-
somiasis is assumed to be eliminated. Diagnosis of infec-
tion is classically based on the detection of parasite eggs
in urine or in feces. However, the method clearly isn’t
sensitive enough to discover infections with low worm
burden [19]. Our study applied two commercially
available serological assays (IHA and ELISA) and an
ultrasensitive research tool, UCP-LF CAA test detectingtic test resultsa
opy IHA ELISA CAA Urine CAA Serum
e Negative Positive Positive Positive
e Negative Positive Negative Positive
Table 2 Test results clinical samples
Diagnostic test
Result Positive Indecisive Negative
Microscopy 0 (0%) 0 (0%) 37 (100%)
IHA 6 (16.2%) 0 (0%) 31 (83.8%)
ELISA 28 (75.7%) 1 (2.7%) 8 (21.6%)
UCAA474 1 (2.7%) 0 (0%) 35 (97.3)%
SCAA150 2 (5.4%) 0 (0%) 33 (94.6%)
S. haematobium past infections (n = 37); supposed cured
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(circulation) and other bodily fluids [9, 20].
In current study group, the classic parasitological
methods on urines samples from 37 old schistosomiasis
cases (treated and considered cured up to 32 years;
confirmed by absence of hematuria) did not reveal S.
haematobium eggs. It supported, as expected, the ab-
sence of active egg shedding by old schistosomiasis cases
in this areas. When using antibody serology, a diagnostic
detecting exposure (active and past infection [21]), only
8 (21.6%) out of 37 samples tested antibody negative.
Consequently, 29 (78.4%) tested antibody positive with
either the IHA or ELISA or both. We note however that
heterogenic distribution of the post-treatment antibody
responses across population may become an issue when
using antibody serology as a diagnostic tool to monitor
elimination and potential re-emergence.
A statistically relevant comparison of IHA and ELISA
in this study has limitations as a consequence of the
relatively small sample set and complication to deter-
mine a proper cutoff threshold for the IHA test. Initially
following the manufacturer’s directions, only 1 antibody
positive case was identified IHA, a sample from a case
that tested negative with the ELISA. Using an adjusted
(lower) cutoff threshold, 5 more positives were identi-
fied, all confirmed with ELISA. Obviously, as the IHA
indicated threshold may not have been optimal for this
sample set, a larger confirmed negative control group
would have been required to determine the appropriate
thresholds. With ELISA 28 positives were identified but
also a negative control returned a positive test result. It
is known that endemic areas where past (high load)Table 3 Test results negative controls
Diagnostic test
Result Positive Indecisive Negative
Microscopy 0 (0%) 0 (0%) 5 (100%)
IHA 0 (0%) 0 (0%) 5 (100%)
ELISA 1 (10%) 0 (0%) 4 (80%)
UCAA475 0 (0%) 0 (0%) 5 (100%)
SCAA150 0 (0%) 0 (0%) 5 (100%)
S. haematobium negative controls (n = 5); supposed exposure freeschistosome infections and poly-parasitism (e.g. with
Plasmodium spp., and Leishmania spp. or other helmin-
thiases [22]) are frequent, serological testing requires
high specificity to avoid false-positive results. Whether
the latter was due to the cross-reactive antibodies
(frequently observed with other serological tests for schis-
tosomiasis [23–25]), autoimmune antibodies [26–28], or
an individual unaware of past exposure, could not be
concluded. In fact antibody specificity may be difficult to
confirm and verify when eggs or antigen detection are
negative [29]. As an alleged better standard assay (in par-
ticular the HAMA-EITB, 100% specificity and sensitivity
for S. haematobium detection; determined with confirmed
cases [5] was not available it is difficult to conclude which
of the two antibody tests applied in this pilot study is most
accurate. However, we do believe that it is important to
use at least two different serological antibody assays in
parallel to achieve sufficient sensitivity in respect to the
presence of Schistosoma antibody, demonstrating expos-
ure. Assuming 100% sensitivity for the active infections in
the serological antibody test protocol, all antibody positive
samples would then require further testing with the UCP-
LF CAA antigen assay to identify the active infections in
this group.
The UCP-LF antigen assay detecting a Schistosoma-de-
rived carbohydrate structure (CAA) in the human blood
circulation (or other bodily fluids), identified two CAA-
positive (clinically asymptomatic) individuals in the 37
previously cured schistosomiasis cases (infection regis-
tered between 1983 and 1994). Detection of CAA is an
unequivocal proof for ongoing infection, the current
presence of life worms as CAA regurgitated by the
worms is rapidly (within hours) cleared from the human
circulation, most likely via urine as the primary route
[30]. In our study, determined CAA levels in sera were
4.2 and 3.5 pg/ml, a level indicative for low worm
burden, potentially the presence of single worm-pair, or
probably single sex (only male or only female) worms as
no eggs are detected. There is some preliminary
evidence indicating that in some cases (e.g. travelers)
CAA serum levels below 1 pg/ml were observed (R.
van Grootveld, 26thECCMID 2016, Amsterdam, the
Netherlands). In vitro studies with worms as well as
studies with experimentally infected animals have in-
dicated that a single worm pair would excrete a daily
amount of CAA in the order of 40 ng, corresponding
to 1–10 pg/ml blood [14]. Expectedly, both cases also
tested antibody positive with ELISA confirming ex-
posure/infection, but scored antibody negative with
IHA. Besides above indicated issues with the IHA
cutoff threshold, immunity to schistosome infections
eventually leading to a decline in antibody response
has been suggested in literature [31] and may explain
the absence of antibody response when using IHA in
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cases active infection was confirmed with a CAA-
positive test result of the paired urine sample. The
other CAA serum-positive was not confirmed with
the applied urine test (UCAA950) and might have re-
quired a larger urine-volume for confirmation of
CAA-positivity was not feasible due to the limited
amount of sample that was made available for UCP-
LF CAA testing at LUMC. As the paired urine sample
was negative and not re-tested with a larger sample
volume, one could challenge the positivity of this
sample. However, a false positive signal is unlikely as
the in serum detected level of CAA was well above
the serum assay cutoff threshold but at a level that
may not always result in a urine-positive test when
testing with less than 2 mL of urine. Furthermore,
PZQ treatment and follow-up testing would be the
ultimate test to confirm disappearance of CAA posi-
tivity, this was not included in the protocol as partici-
pating individuals did not present any schistosomiasis
clinical symptoms.
Clearly, positive UCP-LF CAA test results, whether
obtained with serum or urine, do imply an ongoing in-
fection although not necessarily involve egg shedding.
Assuming no eggs were produced, the CAA-positive test
result of the two egg-negative cases could the presence
of: i) due to drug-treatment sterilized worm pairs; ii) sin-
gle sex worms that survived past treatment; or less
likely; iii) a low grade re-infection by single sex worms
perhaps involving S. bovis. Factors as the presence of im-
mature schistosome, high pre-treatment egg intensities
(indicative of high worm burden), poor drug absorption
and the short life time of PZQ, have been attributed to
the reduced PZQ cure rate in some patients. Serum
levels of circulating anodic antigen (CAA) can be dir-
ectly related to actual worm burden worms. Low CAA
concentrations indicate low worm burden and egg pro-
duction can be easily missed with the common applied
parasitological methods. As worms sometimes may
recover testing after a somewhat longer period should
be part of the protocol to verify the success of the drug
treatment.
Schistosome worms do not multiply in the host, and
in the absence of re-exposure the infection subsides
when the schistosome worm dies, which is usually after
3–5 years [32]. However, the life span of a S. haemato-
bium adult worm may be as long as 30 years [33].
Current study would support the latter potentially in-
volving anti-fecundity immunity [34]. Alternatively Tata
is a sympatric area of S. bovis and S. haematobium;
phylogenetically, S. haematobiumis ancestral to S. bovis
and the ability to infect humans may have been retained
by S. bovis. Because the human skin is thinner than the
skin of a bovine, could be anticipated that S. boviscercariae could penetrate a human without clinical signs.
Moreover, the oviposition site of a potential schistosome
hybrid pair is generally assumed to primarily be
dependent on the species of the male worm and thus
may end up in stool rather than urine [35, 36]. For the
genus specific Schistosoma UCP-LF CAA test, the ovi-
position site doesn’t matter, urine is still an appropriate
test matrix for detection of CAA regurgitated by the
worm, independent of the pathway of egg clearance.
Applying the UCP-LF CAA test for S. haematobium
diagnosis in a close-to-elimination setting in Zanzibar,
United Republic of Tanzania, clearly confirmed that the
empirical prevalence revealed with the UCP-LF CAA
was several-fold higher that the prevalence detected with
a single urine filtration [37]. Studies performed in
People’s Republic of China confirmed the relevant higher
prevalence when comparing egg counts (in stool) with
the urine-antigen test for detection of S. japonicum in-
fections [38]. Further studies must include molecular-
species identification to understand a possible role of S.
bovis infected snails in human Schistosoma infections
bovis-haematobium sympatric areas where urogenital
schistosomiasis is assume to be eliminated. Drug resist-
ance and possible focal human S. bovis infection cannot
be disregarded. Molecular-based approaches such as
multiplex PCR based assaysnot only allow for distinction
of different Schistosoma species as S. bovis and S. hae-
matobium (and others species for immigrants/travelers)
are useful for monitoring and optimizing control strat-
egies and are also applicable for the simultaneous diag-
nosis of several other parasitic infections [39]. For larger
(statistically more relevant) follow-up studies, stratified
testing of high risk groups as e.g. fishermen should also
be included. Evaluation of antigen positive tests using
larger sample volume whenever possible should also be
included. Moreover, testing of children born after trans-
mission stop (2004) would provide important data re-
garding the efficiency of high sensitivity antibody testing
in post-transmission settings.
Conclusion
Morocco was successful in the elimination of urogenital
schistosomiasis caused by S. haematobium. Since 2004,
no new local cases were reported. However, the current
study indicates that some individuals (last remaining
cases) are still harboring Schistosoma worms which ap-
parently are not shedding eggs; this demonstrates the
need for a high sensitivity worm-antigen test as the
UCP-LF CAA test. To prevent reemergence of schisto-
somiasis, national survey should focus on immigrants,
travelers and all potential risk groups as e.g. children,
professionally exposed individuals as canal cleaners, car
washers and fishermen) directly with UCP-LF CAA in-
dependent of their antibody test result The UCP-LF
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species, including veterinarian ones. In Morocco in
sympatric Schistosoma areas as Tata, potential infection
with S. bovis should be taken into consideration. The
species identification in Schistosoma infected individuals
(identified with the UCP-LF CAA test) would require a
molecular approach.
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